- Home
- ELMD vs CRBP Comparison
ELMD vs CRBP Comparison
Compare ELMD & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELMD | CRBP |
|---|---|---|
| Founded | 1992 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.1M | 184.4M |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ELMD | CRBP |
|---|---|---|
| Price | $38.08 | $8.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $36.00 | ★ $45.50 |
| AVG Volume (30 Days) | 48.4K | ★ 707.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $54,716,000.00 | $4,822,272.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | $116.00 |
| P/E Ratio | $40.92 | ★ N/A |
| Revenue Growth | 13.83 | ★ 97.62 |
| 52 Week Low | $17.73 | $6.73 |
| 52 Week High | $40.00 | $20.56 |
Technical Indicators
Market Signals| Indicator | ELMD | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 44.84 |
| Support Level | $23.47 | $8.04 |
| Resistance Level | $40.00 | $8.54 |
| Average True Range (ATR) | 1.98 | 0.46 |
| MACD | -0.38 | 0.10 |
| Stochastic Oscillator | 64.75 | 68.62 |
Price Performance
Historical ComparisonAbout ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.